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Background: Meropenem is a carbapenem antibiotic commonly used in critically ill patients to treat severe
infections. The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as
from clinical studies addressing selected populations, often excluding the elderly and also patients with renal
failure. Our aim was to study PK of meropenem in a broader population of septic critically ill patients.
Methods: We characterized the PK of meropenem in 15 critically ill patients during the first 36 hrs of therapy.
Aditionally, whenever possible, we collected a second set of late plasma samples after 5 days of therapy to evaluate
PK intra-patient variability and its correlation with clinical course.
Patients received meropenem (1 g every 8 hrs IV). Drug plasma profiles were determined by high-performance
liquid chromatography. The PK of meropenem was characterized and compared with clinical parameters.
Results: Fifteen septic critically ill patients (8 male, median age 73 yrs) were included. The geometric mean of the
volume of distribution at the steady state (Vss)/weight was 0.20 (0.15-0.27) L/kg. No correlation of Vss/weight with
severity or comorbidity scores was found. However the Sequential Organ Failure Assessment score correlated with
the Vss/weight of the peripheral compartment (r
2 = 0.55, p = 0.021). The median meropenem clearance (Cl) was 73.3
(45–120) mL/min correlated with the creatinine (Cr) Cl (r2 = 0.35, p = 0.033).
After 5 days (N = 7) although Vss remained stable, a decrease in the proportion of the peripheral compartment (Vss2)
was found, from 61.3 (42.5-88.5)% to 51.7 (36.6-73.1)%. No drug accumulation was noted.
Conclusions: In this cohort of septic, unselected, critically ill patients, large meropenem PK heterogeneity was
noted, although neither underdosing nor accumulation was found. However, Cr Cl correlated to meropenem Cl
and the Vss2 decreased with patient’s improvement.
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Meropenem is a carbapenem antibiotic with a broad an-
tibacterial spectrum, commonly used in critically ill pa-
tients to treat severe infections. Its dose and schedule
are based on pharmacokinetic (PK) data mostly obtained
from healthy volunteers, as well as from clinical studies
[1]. However in critically ill patients, seldom evaluated,
this drug often presents different PK behaviour, and* Correspondence: joaogpster@gmail.com
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distribution, and reproduction in any mediumconventional dosing may fail to provide adequate anti-
biotic concentrations [2-4] due to both fluid shifts and
therapeutic interventions. Moreover elderly patients and
patients with renal failure are commonly excluded from
PK studies and, therefore, it may be even more difficult
to generalize the results.
Some populations, especially those with augmented re-
nal clearance seem to be at special risk of sub-therapeutic
drug concentration. Therapeutic drug monitoring has
been proposed to minimize dosage inadequacy, reducing
the occurrence of sub-therapeutic concentrations or drug
accumulation [5]. Our purpose was to characterize the
concentration time profile of meropenem in a broaded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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stages of infection treatment, to determine if the recom-
mended dose resulted in adequate plasma concentrations,
according to the minimal inhibitory concentration (MIC)
of susceptible bacteria. We also intended to characterize
PK late profile, after at least 5 days of therapy, in particular
volume of distribution at steady state (Vss) and clearance
(Cl), to unveil changes on drug PK behaviour during pa-
tient clinical course, and consequently the need for a dos-
age adjustment during therapy [6].
Methods
The study was approved by the Ethics Committee of the
Centro Hospitalar de Lisboa Ocidental. All patients or
their legal representatives provided written informed
consent.
Infected critically ill patients requiring intravenous
meropenem (by decision of the attending physician), ad-
mitted to the intensive care unit (ICU) between May of
2009 and May of 2010, were recruited, irrespectively of
comorbidities or of renal function. Only patients recei-
ving renal replacement therapy were excluded.
All patients received 1000 mg of meropenem every
8 hrs by an intravenous central line infusion during
30 minutes. The exact duration of the infusion was reg-
istered for accurate PK calculations. The line was flushed
after meropenem infusion to ensure administration of
the entire vial of the drug.
Collected data (Table 1) included Simplified Acute
Physiology Score (SAPS) II score [7], Sequential OrganTable 1 Demographic and clinical data
Patient Gender Age (years) Weight (kg) MV Cr Cl (mL/min)
1 M 73 77 No 76.7
2 F 58 55 Yes 25.0
3 F 77 65 No 66.7
4 M 79 78 No 23.3
5 F 78 85 Yes 81.7
6 M 73 78 Yes 65.0
7 F 76 80 Yes 43.3
8 M 53 60 No 15.0
9 F 71 90 Yes NA
10 M 41 80 Yes 116.7
11 M 51 70 Yes 41.7
12 F 90 75 Yes NA
13 M 34 63 Yes 95.0
14 M 67 80 Yes 226.7
15 F 76 100 No 51.7
Median [IQR] 73 [21] 78 [12.5] 65.0 (40)
Surgery was considered when was performed in the last 24 h before patients’ admi
ventilation; Cr Cl – Creatinine Clearance; Vasop – Vasopressors; Charlson – Charlson co
organ failure assessment score; IQR – Interquartile range; NA-Not available.Failure Assessment (SOFA) [8] score on the day of sam-
ple collection, Charlson comorbidity score [9], measured
creatinine (Cr) Cl (in 4 hrs urine samples).Sampling
Sampling was performed within the first 36 hrs after
starting antibiotic therapy (early samples) and repeated,
whenever possible, in the 5th or 6th day of therapy (late
samples). Five mL blood samples were collected into
heparin-lithium test tubes immediately before the begin-
ning of infusion and after 15, 30, 45, 60, 90, 120, 180,
360 and 480 min of the start of antibiotic infusion,
which covers the times of expected peak and trough
drug concentrations. The exact time of collection of the
sample was registered. Blood samples were immediately
centrifuged at 3000 rpm (roughly 1000*g) and at 4°C,
during 10 min. Two mL of plasma aliquots were sepa-
rated into polypropylene tubes containing an equal vol-
ume of 3-(N-morpholino) propanesulfonic acid (MOPS)
as stabilizing solution. The mixture was immediately fro-
zen at -40°C before being transferred into -80°C (within
48 hrs), where were kept pending analysis. Drug quanti-
fications were made within 3 months as of collection.Analytical determinations
The concentration of meropenem in plasma was de-
termined by high-performance liquid chromatography
(HPLC). Separation was performed at 35°C using a
XTerra® MS C18 cartridge (Waters, inc.) equippedInfection focus Vasop Surgery Charlson SAPS II SOFA
Lung Yes No 4 26 4
Lung No No 3 44 5
Intra-abdominal No Yes 9 48 4
Intra-abdominal No Yes 6 38 2
Bacteremia No No 9 47 4
Unknown Yes Yes 5 43 8
Intra-abdominal Yes Yes 3 72 8
Skin/Soft tissue Yes No 6 34 6
Intra-abdominal No Yes 6 37 3
Intra-abdominal No No 1 35 5
Lung Yes No 4 50 9
Central nervous system No Yes 6 58 6
Lung No No 0 32 2
Lung No No 3 47 4
Intra-abdominal No Yes 3 47 2
4 [3] 44 [11.5] 4 [2.5]
ssion to the Intensive Care Unit. M- Male; F-Female; MV – Invasive mechanical
morbidity score; SAPS II – Simplified acute physiology score II; SOFA – Sequential
Figure 1 Concordance between predicted and observed
meropenem concentration profile in patient #11, either in the
early (panel A) or in the late phase (panel B) of therapy. The
model was considered to be well adjusted.
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The UV detection was performed at 300 nm.
At the time of analysis, samples were thawed at room
temperature. One mL of plasma sample spiked with erta-
penem (as internal standard) was loaded into the car-
tridge. The cartridges were washed two times with 1 mL
of phosphate buffer and eluted with 1 mL of acetonitrile.
The eluted solutions were evaporated under vacuum, at
room temperature. The residue was dissolved in 60 μL of
pure water and injected into the HPLC system.
The mobile phase consisted of a mixture of 92% phos-
phate buffer (pH 7.4) and 8% acetonitrile pumped at
1 mL/min. The autosampler temperature was kept at
4°C and the injection volume was 5 to 25 μL.
This method showed to be linear over a range of
0.35-100 mg/L of meropenem concentration with a cor-
relation coefficient always >0.998. Intra-assay accuracy
ranged from −5.5% to −1.8% and precision was less than
3.9%. Inter-assay accuracy ranged from −8.1% to −1.4%
and precision was less than 4.8%. The lower limit of
quantification was 0.35 mg/L.
The method has also showed to be sensitive and spe-
cific in plasma samples obtained from intensive care pa-
tients not receiving meropenem, but a large number of
other drugs commonly used in critically ill patients (in-
cluding sedatives, vasopressors and other antibiotics).
Pharmacokinetics
Data were analyzed by WinNonlin 5.0.1 software
(Pharsight Corp., Mountain View, California). A two-
compartment model with zero order input and first
order elimination was fitted into meropenem plasma
profiles, using the least squares method. The model
is considered to be well adjusted, with a mean r2 of
0.95 (ranging from 0.77 to 1.00) – Figure 1. The fol-
lowing PK parameters were calculated: elimination
half-life (t1/2), volume of distribution at steady state
associated to the central (Vss1) and to the peripheral
(Vss2) compartments, area-under-the concentration-
time curve (AUC) and total serum meropenem Cl.
We also measured trough concentrations to assess the
possibility of drug accumulation.
The relationship between both meropenem Cl and Vd
on one hand, and clinical relevant characteristics on the
other hand, especially Cr Cl, SOFA score and Charlson
comorbidity score, were assessed. A second set of late
samples were collected whenever possible. We evaluated
the differences between early and late meropenem PK to
evaluate its relationship with patients’ improvement.
Finally we evaluated ability of conventional dose of mer-
openem to achieve a time over minimal inhibitory con-
centration (T >MIC) of 100%, assuming a MIC of 2 mg/L
(the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for Pseudomonas aeruginosa).Statistical analysis
Descriptive statistical analysis was performed. Contin-
uous variables were expressed as median [interquartile
range]. The PK parameters were expressed as geometric
mean (95% confidence interval of the mean) to account
for the log distribution of the data.
Correlations between severity and comorbidity scores
with either Vss or Vss2 and between Cr Cl and mero-
penem Cl were assessed using the Spearman rank cor-
relation test and paired samples were assessed by the
Wilcoxon signed rank test according to the data non
normal distribution.
Data were analyzed using PASW Statistics v.18.0 (SPSS,
Chicago, IL). All statistics were two-tailed, and signifi-
cance level was defined as p <0.05.
Results
Early meropenem pharmacokinetics
Fifteen critically ill patients (eight male, median age 73
[21] yrs) were included in the study. Their clinical and
demographic data are presented in Table 1.
Despite their old age, their clinical severity was rela-
tively low with a median SOFA score of 4 and a SAPS II
score of 44. Ten patients were receiving invasive me-
chanical ventilation and five were on vasopressors at the
time of the first meropenem measurement. Seven pa-
tients were submitted to an abdominal surgery before
enrolment. One patient died still in the ICU.
Goncalves-Pereira et al. BMC Pharmacology and Toxicology 2014, 15:21 Page 4 of 7
http://www.biomedcentral.com/2050-6511/15/21Individual and geometric mean of PK parameters mea-
sured at the first 36 hrs of antibiotic therapy are shown
in Table 2. The geometric mean of Vss, normalized to
patients’ weight, at the early stage of treatment was 0.20
(0.15-0.27) L/kg. No significant correlation of Vss/weight
was found with either SOFA score (r2 = 0.25, p = 0.068),
SAPS II (r2 < 0.01, p = 1.0) or Charlson comorbidity
score (r2 = 0.06, p = 0.389). However the SOFA score was
correlated with the Vss2/weight (r
2 = 0.55, p = 0.002). Mer-
openem Cl geometric mean was 73.3 (45–120) mL/min,
which was significantly correlated with the measured Cr
Cl (r2 = 0.35, p = 0.033).
Fourteen (93%) patients had meropenem concentrations
at 8 hrs above the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) for Pseudomonas aerugi-
nosa (2 mg/L) and therefore had a T >MIC of 100%. Only
one had a trough concentration below that threshold
(Table 2). Six patients had a trough concentration higher
than 8 mg/L (4 times above the same threshold).
No adverse effects related to the antibiotic infusion
were reported.
Evolution of meropenem pharmacokinetics
In seven patients a late set of samples were collected.
Early discharge from the ICU (3 patients), de-escalation
of the antibiotic therapy (3 patients), incomplete data (1Table 2 Initial meropenem pharmacokinetic parameters
Patient N° Vss Vss/weight Vss2/Vss AUC Cl
L L/Kg % L/mg.h mL/m
1 19.6 0.25 50.6% 157.1 106.7
2 NA NA NA 264.7 63.3
3 13.6 0.21 56.3% 253.3 65
4 13.6 0.17 78.4% 160.1 103.3
5 13.4 0.16 51.8% 129.2 128.3
6 32.7 0.42 93.7% 134.9 123.3
7 18.6 0.23 73.6% 479.2 35
8 14.9 0.25 88.7% 465.9 35
9 6.7 0.07 90.4% 232.5 71.7
10 13.0 0.16 58.4% 139.5 120
11 20.9 0.30 68,6% 107.3 155
12 13.6 0.18 79.2% 304.2 55
13 17.1 0.27 34.9% 81.4 205
14 22.5 0.28 53.1% 120.7 138.3
15 13.0 0.13 68.6% 315.3 53.3
Geometric mean 15.7 0.2 63.1% 190.2 73.3
95% CI 12.7-19.4 0.15-0.27 52.7-75.5% 138.4-261.4 45-12
Vss – Volume of distribution at steady state; Vss2 - Volume of distribution at steady s
Cl – Meropenem clearance; T1/2 – Half life; NA- Data not available; IQR – Interquartil
time that meropenem concentration was above 2, 4 and 8 mgL.patient) and withdrawal of consent (1 patient) precluded
the completion of a second PK profile in the 8 patients.
In this subset of patients, the Vss/weight slightly de-
crease, from 0.25 (0.17-0.36) L/kg to 0.23 (0.1-0.53) L/kg
from the early to the late set of measurements (Table 3).
This difference was associated with a relative decrease of
the weight of the Vss2, roughly 10% in 5 days, from 61.3
(42.5-88.5)% to 51.7 (36.6-73.1)%. Significant inter-
patient variability was again noted.
In these 7 patients no accumulation of meropenem
was found from the early to the late set of samples.
However in 4 of them a trough concentration below
2 mg/dL was noted, probably related with the improve-
ment in renal function. This translated in a lower T >MIC
at this time point.
Discussion
In this study we evaluated the PK of meropenem in 15
septic critically ill patients. We found important hetero-
geneity of both Cl, which parallels Cr Cl, and of Vss.
Moreover, we noted a relative decrease of Vss2, in parallel
with patients’ improvement (assessed by the SOFA
score). Despite the variability of the PK parameters, only
one of our 15 patients had a trough level lower than
1 mg/L in early samples and no significant meropenem
accumulation between early and late samples were noted.T1/2 Peak Trough T > 2 mg/L T > 4 mg/L T > 8 mg/L
in h mg/L mg/L 100% 90% 70%
2.9 63.3 3.0 100% 100% 100%
1.5 NA 11.9 100% 100% 100%
2.6 94.1 8.6 100% 100% 85%
1.7 102.3 4.8 100% 85% 50%
1.3 80.1 2.7 100% 90% 65%
3.4 52.0 3.0 100% 100% 100%
6.4 84.7 NA 100% 100% 100%
5.0 91.3 NA 100% 100% 75%
1.4 192.5 4.4 100% 75% 50%
1.5 85.1 2.4 100% 75% 50%
1.9 58.6 2.9 100% 100% 100%
3.5 119.8 8.6 75% 50% 35%
1.3 56.9 0.6 100% 100% 55%
2.1 48.4 4.1 100% 100% 100%
3.3 124.2 12.5 100% 90% 70%
2.3 85.9 3.8 100% 100% 100%
0 1.8-3.1 69.2-106.6 2.3-6.2
tate (peripheral compartment); AUC – Area under the concentration-time curve;
e range; 95% CI - 95% confidence interval of the mean; T > − Percentage of
Table 3 Comparison of early and late clinical and
pharmacokinetic parameters in the 7 patients who
completed two pharmacokinetic assessments
Early Late P-value*
Cr Cl (mL/min) 66.7 [31.7] 106.7 [46.7] 0.128
SOFA 6 [3.5] 3 [1] 0.042
Vss (L) 18.5 (13.0-26.4) 17.3 (7.3-41.0) 0.866
Vss/Weight (l/kg) 0.25 (0.17-0.36) 0.23 (0.1-0.53) 0.866
Vss2/Vss (%) 61.3 (42.5-88.5) 51.7 (36.6-73.1) 0.176
Cl (mL/min) 120 (75–188.3) 135 (73.3-228.3) 0.398
Trough (mg/L) 2.6 (1.1-6.4) 1.5 (0.4-5.9) 0.172
Cr Cl – Creatine Clearance; SOFA- Sequential organ failure assessment score;
Vss – Volume of distribuition at steady state; Vss2 – Volume of distribution at
steady state of the peripheral compartment; Cl – Meropenem Clearance;
Early – Parameters measured within the first 36 hrs of meropenem therapy;
Late – Parameters measured after the 5th day of meropenem therapy.
*Wilcoxon signed ranks test. Data presented as geometric mean (95%
confidence interval of the mean) or median [IQR].
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meropenem PK in septic patients have generally reported
high Vss and Cl, with large inter-patient variability, exceed-
ing a twofold variation [10-12]. This variability of PK pa-
rameters in septic patients treated with meropenem was
noted both in the same patient during infection treatment
and between different patients [10].
The mean meropenem Vss in patients with ventilator
associated pneumonia has been reported to be as high as
0.47 L/kg [12] or as low as 0.11 L/kg [11]. In our study
the geometric mean Vss was 0.20 L/kg, which is in the
range of the values reported in volunteers [1], although
we noted large inter-patient variability (Table 2).
The β-lactam antibiotics are hydrophilic drugs usually
eliminated by the kidney. In septic critically ill patients
Cr Cl is commonly aumengted and this has been shown
to occur in septic surgical or trauma patients [13] as well
as in medical patients [14]. Moreover patients with normal
plasma creatinine frequently have aumengted Cr Cl that
may be unrecognized without direct measurement [15].
Meropenem Cl has been noted to be correlated, as in
our study, with the Cr Cl [16] and increases in drug Cl
may lead to underexposure and facilitate the emergence
of resistance, especially when long antibiotic courses are
used. Nevertheless the relationship with Cr Cl is not lin-
ear and changes in Cr Cl may not reliably predict varia-
tions in β-lactam PK [17]. In a study addressing 11
surgical patients no change in meropenem Cl was noted
between the first and the fourth day of therapy, despite
an increase of roughly 25% in Cr Cl [18], which was
similar to our results. In the same cohort the authors
again noted a decrease, although non significant, of mero-
penem mean Vss, from 0.22 ± 0.06 to 0.17 ± 0.06 L/kg, ac-
companying clinical improvement [18]. In another study,
addressing 25 critically ill patients (either from the ICU
or from hemato-oncology) [19], the authors noted lowtrough concentrations and T >MIC due to increased Cl
and Vd. Again these differences were only partly explained
by increased Cr Cl. Conversely, drug accumulation oc-
curred in ICU subjects with decreased renal function and
therapeutic drug monitoring (TDM) was advised [19].
Since β-lactam TDM is not widely available, popula-
tion PK models have been proposed. Moreover the mo-
del was improved in one study [20] by the inclusion of
amikacin TDM and correctly predicted Vd and Cl of 4
different β-lactam antibiotics. In another study of popu-
lation PK [21] imipenem Cl was found to be correlated
with patients’ demographic characteristics (age, weight
and height) as well as with Cr Cl.
In our study we were able to unveil a relative decrease
of the Vss2 during treatment, which maybe consequence
of the reversal of fluid shifts and decrease of the intersti-
tial compartment fluid volume [22].
Changes in PK may lead either to sub-therapeutic con-
centrations or to drug accumulation. In a study, 25% of
patients with severe sepsis or septic shock did not at-
tained the intended target after the first dose of 1 g of
meropenem; this was due to a large Vss (0.43 [Interquartile
range 0.43] L/kg) [23]. Also an increase in Cl and a lower
T >MIC of β-lactam antibiotics, may follow the increase
in Cr Cl, noted in several septic critically ill patient, and
contributed to treatment failure [24]. Several of these
studies excluded patients with the lower Cr Cl (either
measured or estimated). On the contrary, we choose to in-
clude all critically ill septic patients in order to increase
the external validity. However we aknowledge that this
may also help to explain why we only found one patient
with augmented renal [25] or meropenem Cl.
To overcome the altered PK of critically ill patients
TDM has been proposed [5]. However, currently the-
rapeutic target concentrations are poorly defined and
β-lactam TDM is seldom available in most hospitals.
Proposed targets of β-lactam antibiotics ranged between
40 to 60% of T >MIC [26] but a T >MIC as high as 100%
[27] or 40% T > 4*MIC [23] has also been suggested.
Acording to our findings, the use of TDM seems to be not
usefull in an unselected population of critically ill septic
patients. In fact, only one of our patients had a Cr Cl
higher than normal, above 130 mL/min (Table 1). How-
ever that same patient was the only one who did not
attained a T >MIC of 100%. Besides, we did not find evi-
dence of either underdosing or drug accumulation be-
tween early and late measurements.
However we believe that this strategy may be usefull
for selected patients at high risk of PK changes, par-
ticularly those with augmented renal clearance [28], al-
though better definition of the target concentrations is
probably needed.
Continuous infusion of β-lactam antibiotics has also
been proposed to achieve an improved concentration
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despite its biological plausibility, has produced disapoint-
ing results so far. Two recent randomized prospective
studies both unveiled a non-significant decrease in hos-
pital mortality with continuous infusion of β-lactam an-
tibiotics, despite higher microbiological response. The
first one included 60 patients treated with piperacillin/
tazobactam, meropenem or ticarcillin [31]. Hospital mor-
tality was 10% in the continuous group versus 20% in the
intermittent arm (p = 0.47). Another study included 240
patients treated with a high dose of meropenem (6 g/day),
either by continuous or intermittent infusion [32]. Hos-
pital mortality was 17.5% vs 23.3%, respectivelly (p = 0.34).
Similarly, a meta-analysis of another 14 prospective stud-
ies [33] and a retrospective matched case–control study of
piperacillin/tazobactam [34], again failed to show a sur-
vival benefit. It should be noted that, if changes in the Vd
and high MIC are not considered, with continuous infu-
sion concentration of the antibiotic might be always under
the MIC.
Overall it seems that both these strategies, continuous
infusion of β-lactam antibiotics and TDM, are probably
helpful in the presence of bacteria with a high MIC
or a high inoculum or in the presence of augmented
renal clearance [35], especially in the early phases of
therapy [36].
This study has some limitations namely it is single
center and included a relativelly small number of pa-
tients. Beside we did not measured patients weight daily
although we were not able to find a correlation between
patients’ fluid balance and Vd. Nevertheless it also had
some strengths: only critically ill septic patients were in-
cluded, different infection focus were studied and an
evaluation of early as well as late PK parameters was
performed.
In the present study we confirmed the PK adequacy
of the commonly used dose of meropenem to treat
an unselected population of septic critically ill patients
not receiving renal replacement therapy. As a result
we did not find any evidence that the generalized use
of meropenem TDM would be useful or cost-effective.
Identification of sub-groups of patients most likely to
benefit from this pratice should be performed before the
general use of TDM monitoring can be recommended.Conclusions
In a population of septic critically ill patients mero-
penem PK was found to have important heterogeneity,
especially Cl and Vss. A decrease of Vss2 was noted to
parallel patients’ improvement in the second merope-
nem PK assessment. Trough levels were found to be
above 2 mg/dL in almost all patients at early samples
but only in half of patients in late samples.Abbreviations
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